The FDA has approved Otarmeni, the first gene therapy for genetic hearing loss, marking a major milestone in medicine for children born deaf. Delivered through a single injection, it replaces a faulty gene that enables the inner ear to transmit sound to the brain. In trials, 16 of 20 children showed meaningful hearing improvement, with some able to detect whispers. Unlike cochlear implants, this approach restores hearing biologically without external devices. Regeneron has also announced it will provide the treatment at no cost in the U.S., setting an early precedent for access. Read more here.